Copeptin and Nonalcoholic Fatty Liver Disease

Status unconfirmed

Conditions studied: NAFLD

In brief

Copeptin, a surrogate marker for vasopressin, has been found to be elevated in metabolic disorders including obesity and diabetes, which are disorders both associated with nonalcoholic fatty liver disease (NAFLD), and therefore suggest a potential role for vasopressin in the pathogenesis of NAFLD. The investigators intend to investigate if there is an association of vasopressin with the presence and severity of NAFLD.

Key facts

Study ID

NCT03254563

Run by

University of Colorado, Denver

People needed

60

Starts

2018-06-19

Expected to finish

2021-06-01

Last updated by the study team

2021-02-10

Who can join

Age: 30 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients age 30-75
• BMI 30-40
• Presence of fatty liver on ultrasound

You may not qualify if…

• Diabetes mellitus (determined by prior HbA1c, fasting glucose, and/or random glucose in the last three months according to ADA criteria),
• Medication known to affect insulin sensitivity e.g. metformin, thiazolidinediones, systemic steroids, atypical antipsychotics),
• Fibrates,
• eGFR <45 ml/min/1.73m2 by MDRD equation(11),
• Pregnancy,
• Breast feeding,
• Sodium <135 mEq/L,
• Diabetes insipidus,
• Liver disease other than NAFLD (including obstructive liver disease),
• ALT or AST>60 IU/L,
• Hepatic steatosis on ultrasound for the non-NAFLD group,
• Congestive heart failure,
• Patients who consume >20g of ETOH a day,
• Patients found to have Cushing's disease based upon 24 hour urine results (Urine Free cortisol >2x upper limit of normal).
• Patient's with pacemakers
• Off of Coenzyme Q for 6 months.

Where it is running

• University of Colorado — Aurora, Colorado, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.